Kimberly Burlison

Head of Market Access, North America at Orchard Therapeutics

Speaker

Kimberly Burlison is a results-driven leader with extensive experience in market access strategy and commercialization within the biotech and managed care sectors. As the Head of Market Access at Orchard Therapeutics, Kim leads the U.S. commercial market access efforts for Lenmeldy, a groundbreaking gene therapy for Metachromatic Leukodystrophy (MLD), a rare and fatal pediatric disorder.

Prior to joining Orchard in 2024, Kim served as Director of Market Access at EQRx, where she spearheaded payer engagement strategies, securing broad formulary coverage for oncology therapeutics. She also held key roles within Blue Cross Blue Shield Association (BCBSA), overseeing pharmacy benefit management and strategic partnerships.

With a deep passion for patient-centered care and innovative access solutions, Kim brings a wealth of expertise to the evolving landscape of gene therapy commercialization.